Redeye initiates coverage of Calmark
2020-10-14 08:15:00
Redeye initiates coverage on Calmark, a Swedish diagnostics company offering point of care testing for biomarkers in newborns. Commercialization is now starting, and we believe further regulatory approvals are underway. Calmark is rather uniquely positioned, in our view, and our supportive valuation reflects a base case of significant sales ramp-up in 2022-23. While not in our numbers yet, the possibility of Covid-19 relevance adds spice.
Read more and download the Research Report
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/